We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Glycated Hemoglobin Testing Simplifies Diabetes Screening In Remote Area

By LabMedica International staff writers
Posted on 21 Jul 2015
Print article
The Bayer DCA 2000+ Analyzer is a point-of-care diabetes management platform that performs both glycated hemoglobin HbA1c and microalbumin / creatinine tests in minutes
The Bayer DCA 2000+ Analyzer is a point-of-care diabetes management platform that performs both glycated hemoglobin HbA1c and microalbumin / creatinine tests in minutes (Photo courtesy of Siemens Healthineers - Laboratory Diagnostics)
In contrast to the current diagnostic blood glucose testing, assessment of glycated hemoglobin A (HbA1c) requires no fasting and this makes it more suitable for opportunistic testing, and results in fewer missed diagnoses.

Early identification of diabetes and associated complications provides an opportunity to start effective preventive treatment that reduces the subsequent development or progression of macrovascular and microvascular disease.

Scientists at the Rural Clinical School, University of Western Australia (Broome, Australia) performed a cross-sectional study that independently classified 255 Aboriginal Australians aged 15 years or more without confirmed diabetes and due for diabetes testing at participating clinics. These were six primary health care sites in the Kimberley region of Western Australia from September 1, 2011, to November 30, 2013.

Capillary blood HbA1c concentration was measured in a finger-prick blood sample collected by primary health care providers and analyzed on a point-of-care DCA 2000+ Analyzer (Siemens/Bayer; Erlangen, Germany). Venous plasma HbA1c levels were measured using an automated immunoassay, with anticoagulated whole blood specimens automatically hemolysed by HbA1c hemolysis reagent in the predilution cuvette on a cobas Integra 800 analyzer (Roche Diagnostics; Basel, Switzerland). Venous plasma glucose (PG) levels were measured by enzymatic assay (glucose oxidase spectrophotometric dry chemistry) on a Vitros 250 Analyzer (Ortho Clinical Diagnostics; Rochester, NY, USA).

All participants with a confirmed diagnosis of diabetes were identified by the HbA1c algorithm as having either diabetes including 15 cases or 5 cases of prediabetes. Those classified as having prediabetes are expected to be followed up more frequently, reducing the chance of diabetes in these patients being missed for any length of time. HbA1c testing is clearly more likely to detect diabetes than glucose testing. The investigators found that participants were significantly more likely to receive a definitive test result within seven days using the HbA1c test, and were more likely to be followed up if an initial result was abnormal.

Julia V. Marley, PhD, the lead author said, “Our study shows that adopting the Kimberley HbA1c algorithm may simplify the testing process in previously undiagnosed individuals and provide a timelier and more accurate diagnosis of diabetes for Aboriginal people and other high-risk remote populations in Australia and elsewhere in the world.” The study was published on July 6, 2015, in the Medical Journal of Australia.

Related Links:

University of Western Australia
Siemens/Bayer 
Roche Diagnostics 



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.